TY - JOUR
T1 - Tumor growth inhibitory effects of SMANCS, a poly (styrene-maleic acid) conjugated derivative of neocarzinostatin, on various tissue culture cells
AU - Suzuki, F.
AU - Okuno, Y.
AU - Maeda, Y.
AU - Maeda, H.
PY - 1987/12
Y1 - 1987/12
N2 - Growth inhibitory effects of neocarzinostatin (NCS), and its conjugated derivative with poly (styrene-maleic acid), SMANCS, were examined on various tissue culture cells consisting of 13 lymphatic and 7 non-lymphatic cells (15 cell lines, 5 primary culture cells; 14 in suspension culture cells, 6 in monolayer cells). Both agents showed almost similar concentrations for the growth inhibition against 5 non-lymphatic cell lines (an average minimum growth inhibitory concentration of NCS, 0.076 microgram/ml, and SMANCS, 0.094 microgram/ml, a ratio of 1 : 1.24 (W/W), or 1.0 : 0.9 (mol/mol]. However, SMANCS showed a much less growth inhibitory effects against lymphatic 10 cell lines than NCS. Namely, an average 50% growth inhibitory concentration of NCS was 0.019 microgram/ml whereas that of SMANCS was 0.091 microgram/ml (a ratio of 1 : 4.79). From the consideration of each molecular weight, this ratio is 1 : 3.6. Similar results were obtained in experiments in which 2 primary non-lymphatic cells and 3 primary lymphatic cells were used. Although the largest drawback with NCS was known to be leukopenia, present results indicated the less toxicity of SMANCS than NCS on lymphatic cells and may provide a positive aspect of the new derivative, such as less incidence of leukopenia.
AB - Growth inhibitory effects of neocarzinostatin (NCS), and its conjugated derivative with poly (styrene-maleic acid), SMANCS, were examined on various tissue culture cells consisting of 13 lymphatic and 7 non-lymphatic cells (15 cell lines, 5 primary culture cells; 14 in suspension culture cells, 6 in monolayer cells). Both agents showed almost similar concentrations for the growth inhibition against 5 non-lymphatic cell lines (an average minimum growth inhibitory concentration of NCS, 0.076 microgram/ml, and SMANCS, 0.094 microgram/ml, a ratio of 1 : 1.24 (W/W), or 1.0 : 0.9 (mol/mol]. However, SMANCS showed a much less growth inhibitory effects against lymphatic 10 cell lines than NCS. Namely, an average 50% growth inhibitory concentration of NCS was 0.019 microgram/ml whereas that of SMANCS was 0.091 microgram/ml (a ratio of 1 : 4.79). From the consideration of each molecular weight, this ratio is 1 : 3.6. Similar results were obtained in experiments in which 2 primary non-lymphatic cells and 3 primary lymphatic cells were used. Although the largest drawback with NCS was known to be leukopenia, present results indicated the less toxicity of SMANCS than NCS on lymphatic cells and may provide a positive aspect of the new derivative, such as less incidence of leukopenia.
UR - http://www.scopus.com/inward/record.url?scp=0023492298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023492298&partnerID=8YFLogxK
M3 - Article
C2 - 2961306
AN - SCOPUS:0023492298
SN - 0385-0684
VL - 14
SP - 3305
EP - 3312
JO - Gan to kagaku ryoho. Cancer & chemotherapy
JF - Gan to kagaku ryoho. Cancer & chemotherapy
IS - 12
ER -